Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) EBITDA: 2010-2025

Historic EBITDA for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to -$2.5 million.

  • Anika Therapeutics' EBITDA rose 91.39% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.3 million, marking a year-over-year increase of 66.61%. This contributed to the annual value of -$57.2 million for FY2024, which is 30.36% up from last year.
  • As of Q3 2025, Anika Therapeutics' EBITDA stood at -$2.5 million, which was up 4.16% from -$2.6 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' EBITDA registered a high of $6.7 million during Q2 2021, and its lowest value of -$62.4 million during Q4 2023.
  • For the 3-year period, Anika Therapeutics' EBITDA averaged around -$13.5 million, with its median value being -$4.9 million (2024).
  • As far as peak fluctuations go, Anika Therapeutics' EBITDA spiked by 189.75% in 2021, and later crashed by 1,518.55% in 2023.
  • Over the past 5 years, Anika Therapeutics' EBITDA (Quarterly) stood at -$6.2 million in 2021, then spiked by 37.76% to -$3.9 million in 2022, then tumbled by 1,518.55% to -$62.4 million in 2023, then spiked by 63.21% to -$22.9 million in 2024, then surged by 91.39% to -$2.5 million in 2025.
  • Its last three reported values are -$2.5 million in Q3 2025, -$2.6 million for Q2 2025, and -$4.2 million during Q1 2025.